Apidel SA is an early-stage, privately-funded Swiss pharmaceutical company based in Geneva. Founded in 2011 by two University of Geneva researchers and an experienced industry executive, Apidel specializes in providing proprietary drug delivery solutions which enable more effective, safer and cost effective therapeutic products, which also help patients adhere to their prescribed medical treatment.
Apidel’s proprietary technologies allow effective drugs, new and established, to be formulated into new pharmaceutical products with increased therapeutic potential. This provides a platform for new indications, even for established drug molecules. Apidel develops an internal pipeline of products utilizing approved pharmaceuticals and engages with pharmaceutical partners for joint development of products in various fields. All drugs formulated using Apidel’s proprietary technologies enjoy proprietary status under Apidel’s growing portfolio of granted patents and patent applications.
By applying its technology to previously approved drug molecules, Apidel expects to accelerate the development and lower the clinical and regulatory risk of its product developments. By partnering, Apidel is able to generate revenue at pre-market stage and thereby increase shareholder value by ensuring an extensive pipeline of products.
Apidel’s name is derived from API (Active Pharmaceutical Ingredient) DELivery, which is our primary expertise. Indeed, Apidel’s technical experience in pharmaceutical formulation and in effective drug delivery using polymeric vehicles is unrivalled.

Management

Alan Cookson

Dr. Alan Cookson, CEO is a co-founder of the Company. He brings substantial experience of the pharmaceutical industry both from his career…

Robert Gurny

Prof. Robert Gurny, CSO is co-founder of the Company and co-inventor of the technologies, previously Professor at University of Geneva, he…

Michael Möller

Dr. Michael Möller, Technical Director is co-founder of the Company and co-inventor of the technologies; he is an organic research chemist…

Victoria Sarraf

Victoria Sarraf, Alliance Manager is a licensed Pharmacist (MSc. Pharm., Federal Diploma) and is post-graduated in Management from the…

Thibault Mugnier

Thibault MUGNIER, R&D Project Leader holds a MSc. in Analytical Chemistry. He worked on pharmaceutical development projects within…

Board of directors

James Clark

Mr. James Clark has over 30 years experience in the fields of Pharmaceutical Delivery Systems Licensing and Business Development, Medical…

Rainer Hoffmann

Dr. Rainer Hoffmann joined the Lohmann Group in 1979. Realising the potential for transdermal delivery systems he immediately set to work…

Vincent Lenaerts

Dr. Vincent Lenaerts has a track record as a successful entrepreneur in the bio-pharmaceutical industry creating shareholder value in all…

Alan Cookson

Dr. Alan Cookson is a co-founder of the Company. He brings substantial experience of the pharmaceutical industry both from his career in…

Robert Gurny

Prof. Robert Gurny is co-founder of the Company and co-inventor of the technologies, previously Professor at University of Geneva, he…

Michael Möller

Dr. Michael Möller is co-founder of the Company and co-inventor of the technologies; he is an organic research chemist with extensive…

Scientific advisory board

Jean-Philippe Combal, PharmD, PhD

Jean-Philippe Combal, Pharm.D., Ph.D from Paris University is currently Chief Operating Officer at GenSight Biologics, a clinical stage…

Peter Lichtlen, MD, PhD, BBA

Peter Lichtlen is the Chief Medical Officer at Sucampo Pharmaceuticals Inc. a Nasdaq-listed biopharmaceutical company located in Bethesda…

Francine Behar-Cohen, MD, PhD

Dr. Francine Behar-Cohen  is currently Chief of the ophthalmology unit and Medical Director at the Jules-Gonin hospital in Lausanne.…

Selected collaborations